分析蔗糖铁联合重组人促红细胞生成素注射液在慢性肾衰竭合并肾性贫血患者中的应用效果

Analysis of the application effect of iron sucrose combined with recombinant human erythropoietin injection in patients with chronic renal failure and renal anemia

目的分析蔗糖铁联合重组人促红细胞生成素注射液在慢性肾衰竭合并肾性贫血患者中的应用价值。方法选取80例慢性肾衰竭合并肾性贫血患者,利用随机数字表法将患者划分为对照组(40例,采用重组人促红细胞生成素注射液治疗)、观察组(40例,采用蔗糖铁联合重组人促红细胞生成素注射液治疗)。对比两组患者临床疗效,不良反应发生率,治疗前后血象指标、铁指标、肾功能指标以及生活质量评分。结果观察组患者总有效率95.00%高于对照组的80.00%(P<0.05)。两组不良反应发生率对比,无显著差异(P>0.05)。治疗后,观察组患者的红细胞计数(RBC)(2.98±0.21)×10^(12)/L、血红蛋白(Hb)(88.25±3.95)g/L、红细胞比容(HCT)(25.13±3.53)%均高于对照组的(2.58±0.29)×10^(12)/L、(75.04±3.71)g/L、(22.40±2.96)%(P<0.05)。治疗后,观察组患者的血清铁(SI)、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)高于对照组(P<0.05)。治疗后,观察组患者的尿素氮(BUN)(8.62±2.03)mmol/L、血肌酐(Scr)(176.36±14.50)μmol/L、血尿酸(450.42±65.30)μmol/L均低于对照组的(13.39±2.19)mmol/L、(232.60±18.34)μmol/L、(562.97±98.21)μmol/L(P<0.05)。治疗后,观察组患者的身体活动、睡眠、疼痛、社会孤独感、情绪反应、精力评分分别为(8.27±1.97)、(10.97±1.78)、(10.42±1.49)、(8.31±1.42)、(9.30±1.30)、(8.47±1.65)分,显著低于对照组的(12.69±2.04)、(14.59±2.39)、(13.93±1.78)、(11.48±2.64)、(13.39±2.58)、(13.40±2.38)分(P<0.05)。结论蔗糖铁联合重组人促红细胞生成素注射液治疗慢性肾功能衰竭合并肾性贫血患者,有利于提升临床疗效,增强铁剂吸收,显著改善患者的肾功能和日常生活质量,具有较高的作用价值,值得推广。

Objective To analyze the application value of iron sucrose combined with recombinant human erythropoietin injection in patients with chronic renal failure and renal anemia.Methods A total of 80 patients with chronic renal failure and renal anemia were selected and divided into a control group(40 cases,treated with recombinant human erythropoietin injection)and an observation group(40 cases,treated with iron sucrose combined with recombinant human erythropoietin injection)by random number table method.The clinical efficacy,incidence of adverse reactions,hematological parameters,iron index,renal function index and quality of life score before and after treatment were compared between the two groups.Results The total effective rate of the observation group was 95.00%,which was higher than 80.00%of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the observation group had red blood cell count(RBC)of(2.98±0.21)×10^(12)/L,hemoglobin(Hb)of(88.25±3.95)g/L,and hematocrit(HCT)of(25.13±3.53)%,which were higher than(2.58±0.29)×10^(12)/L,(75.04±3.71)g/L,and(22.40±2.96)%in the control group(P<0.05).After treatment,the serum iron(SI),serum ferritin(SF)and transferin saturation(TAST)of the observation group were better than those of the control group(P<0.05).After treatment,the observation group had blood urea nitrogen(BUN)of(8.62±2.03)mmol/L,serum creatinine(Scr)of(176.36±14.50)μmol/L,and blood uric acid of(450.42±65.30)μmol/L,which were lower than(13.39±2.19)mmol/L,(232.60±18.34)μmol/L,and(562.97±98.21)μmol/L of the control group(P<0.05).After treatment,the scores of physical activity,sleep,pain,social loneliness,emotional response and energy in the observation group were(8.27±1.97),(10.97±1.78),(10.42±1.49),(8.31±1.42),(9.30±1.30)and(8.47±1.65)points,which were significantly lower than(12.69±2.04),(14.59±2.39),(13.93±1.78),(11.48±2.64),(13.39±2.58)and(13.40±2.38)points in the control group(P<0.05).Conclusion For patients with chronic renal failure combined with renal anemia,the combination of iron sucrose and recombinant human erythropoietin injection is beneficial for improving clinical efficacy,enhancing iron absorption,and significantly improving renal function and quality of daily life in patients.It has high therapeutic value and is worth promoting.